(4r-Cis)-1,1-Dimethylethyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate (Ats-8) CAS:125971-94-0

Ats-8 presents exciting possibilities for utilization in pharmaceutical research due to its distinctive structural characteristics and potential pharmacological activities. The combination of the cyanomethyl group, dioxane ring, and acetate functionality in (4r-Cis)-1,1-Dimethylethyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate provides a versatile platform for designing molecules with targeted biological properties. In drug development, researchers can explore the therapeutic potential of Ats-8 by investigating its interaction with protein targets, receptors, or enzymatic pathways. The cyanomethyl moiety may facilitate binding to specific biological targets, modulating their functions and influencing downstream signaling cascades. Moreover, the dioxane ring and acetate group offer opportunities for structural modifications and optimization to enhance biological activity, bioavailability, or metabolic stability of potential drug candidates derived from Ats-8. Through medicinal chemistry studies and pharmacological evaluations, scientists can elucidate the pharmacokinetic and pharmacodynamic properties of Ats-8 and its derivatives. By synthesizing analogs or new chemical entities based on this scaffold, researchers can tailor molecules with desired drug-like characteristics and therapeutic effects. The (4r-Cis)-1,1-Dimethylethyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate scaffold serves as a valuable starting point for designing innovative medications targeting various diseases and medical conditions. Furthermore, the chiral nature of Ats-8 offers the potential for developing enantiomerically pure compounds with improved selectivity and efficacy profiles. By exploring different synthetic routes and structural modifications, scientists can fine-tune the biological properties of Ats-8 analogs for specific therapeutic applications, ranging from oncology to central nervous system disorders. In summary, (4r-Cis)-1,1-Dimethylethyl-6-Cyanomethyl-2,2-Dimethyl-1,3-Dioxane-4-Acetate (Ats-8) represents a promising scaffold in medicinal chemistry, enabling the design and optimization of pharmaceutical agents with diverse pharmacological activities and therapeutic potentials. Its structural complexity and pharmacological versatility underscore its significance in drug discovery programs aimed at addressing unmet medical needs and advancing patient care.